leadf
logo-loader
viewArch Therapeutics, Inc.

Arch Therapeutics CEO looks ahead to positive results on AC5 gel

Arch Therapeutics (OTCMKTS:ARTH, OTCQB:ARTH) CEO Dr. Terry Norchi tells Proactive Investors the biotechnology company is developing a gel called AC5 that seals and protects leaking and bleeding tissue in the human body.

Norchi says the FDA has already seen Arch's application on AC5 and requested additional data to show the product does not cause an allergic reaction when placed on intact skin. The company is conducting a human skin sensitization study for this, and the CEO says he feels positive about the data.

Quick facts: Arch Therapeutics, Inc.

Price: 0.1725 USD

OTCMKTS:ARTH
Market: OTCQB
Market Cap: $33.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Cabral Gold adds 2nd drill rig as company identifies new high-grade veins

Cabral Gold (CVE: CBR-OTC: CBGZF) CEO Alan Carter joined Steve Darling from Proactive Vancouver with news the company has identified at least six new NE trending high-grade veins in the Machichie SW area located immediately north of the MG deposit. Carter telling Proactive what had led them...

2 days, 10 hours ago

2 min read